Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $264,458.30 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $101.95, for a total transaction of $264,458.30. Following the transaction, the senior vice president owned 5,835 shares in the company, valued at approximately $594,878.25. The trade was a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $107.13 on Friday. The stock has a market cap of $6.53 billion, a PE ratio of -7.87 and a beta of 0.50. The business has a fifty day simple moving average of $98.70 and a 200-day simple moving average of $92.22. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12 month low of $47.89 and a 12 month high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.30) EPS. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Ratings Changes

MIRM has been the topic of several research analyst reports. Wolfe Research started coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price on the stock. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Leerink Partners decreased their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, Citizens Jmp upped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Comerica Bank raised its stake in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after buying an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after buying an additional 1,720 shares in the last quarter. Caxton Associates LLP acquired a new position in Mirum Pharmaceuticals in the first quarter worth approximately $217,000. Finally, Empowered Funds LLC increased its holdings in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.